drugset / Trial / NCT05006664
Brentuximab Vedotin in Combination With CHEP in Patient With PTCL
NaSingle-groupOpen-labelTreatment
Summary
A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)
Timeline
- Start
- 2021-10
- Primary completion
- 2024-10
- Completion
- 2024-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 50 mg | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | — |